Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis: Update #1

We have reviewed and updated the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada (CRA/SPARCC) living treatment recommendations for the management of axial spondyloarthritis (axSpA).^1,2 Since its initial publication, the panel felt the need to reassess recommendations relating to treatment with interleukin-17 inhibitors (IL-17i).